Veritas In Silico (TSE:130A) EBIT: 円-437.89 Mil (TTM As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TSE:130A Veritas In Silico Inc TSE:130A
28 GF Score
Price 円433.00
GF Value 円266.78
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Veritas In Silico EBIT?

Veritas In Silico TSE:130A -2.26% 28 EBIT is 円-437.89 Mil as of Jun. 2026. GuruFocus rates TSE:130A with a GF Score™ of 28/100 and a GF Value™ of 円266.78 (Significantly Overvalued). The stock has 4 warning signs investors should review.

Veritas In Silico's earnings before interest and taxes (EBIT) for the three months ended in Jun. 2026 was 円0.00 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Jun. 2026 was 円-437.89 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Veritas In Silico's annualized ROC % for the quarter that ended in Jun. 2026 was 0.00%. Veritas In Silico's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jun. 2026 was %.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Veritas In Silico's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Jun. 2026 was -31.76%.

Veritas In Silico  (TSE:130A) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Veritas In Silico's annualized ROC % for the quarter that ended in Jun. 2026 is calculated as:

ROC % (Q: Jun. 2026 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Mar. 2026 ) + Invested Capital (Q: Jun. 2026 ))/ count )
=0 * ( 1 - 0% )/( (91.405 + 74.952)/ 2 )
=0/83.1785
=0.00 %

where

Invested Capital(Q: Mar. 2026 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=1785.382 - 154.64 - ( 1715.395 - max(0, 226.592 - 1765.929+1715.395))
=91.405

Invested Capital(Q: Jun. 2026 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=1519.286 - 37.715 - ( 1430.305 - max(0, 91 - 1497.619+1430.305))
=74.952

Note: The Operating Income data used here is four times the quarterly (Jun. 2026) data.

2. Joel Greenblatt's definition of Return on Capital:

Veritas In Silico's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jun. 2026 is calculated as:

ROC (Joel Greenblatt) %(Q: Jun. 2026 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Mar. 2026  Q: Jun. 2026
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=0/( ( (0 + max(-176.058, 0)) + (0 + max(-23.686, 0)) )/ 2 )
=0/( ( 0 + 0 )/ 2 )
=0/0
= %

where Working Capital is:

Working Capital(Q: Mar. 2026 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 11.592 + 38.942) - (154.64 + 0 + 71.952)
=-176.058

Working Capital(Q: Jun. 2026 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(1.54 + 11.824 + 53.95) - (37.715 + 0 + 53.285)
=-23.686

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Jun. 2026) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Veritas In Silico's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Jun. 2026 )
=-437.89/1378.615
=-31.76 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Veritas In Silico EBIT Related Terms

Veritas In Silico EBIT Historical Data

* Premium members only.

The historical data trend for Veritas In Silico's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Veritas In Silico EBIT Chart

Veritas In Silico Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
EBIT
-235.51 -138.91 37.62 -212.85 -396.75

Veritas In Silico Quarterly Data
Dec21 Dec22 Sep23 Dec23 Mar24 Jun24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -105.20 -101.53 -108.96 -122.20 0.00

TSE:130A vs VRTX, REGN, MRNA: EBIT Comparison

For the Biotechnology subindustry, Veritas In Silico's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Veritas In Silico EV-to-EBIT vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Veritas In Silico's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Veritas In Silico's EV-to-EBIT falls into.


TSE:130A
28GF Score
Veritas In Silico Inc TSE:130A
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Veritas In Silico EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was 円-437.89 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of 円-437.89 Mil mean?
Veritas In Silico (TSE:130A) has a EBIT of 円-437.89 Mil as of Jun. 2026. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Veritas In Silico.
Is Veritas In Silico's EBIT too high?
Veritas In Silico's current EBIT is 円-437.89 Mil. Overall, Veritas In Silico has a GF Score™ of 28/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Veritas In Silico's EBIT compare to VRTX and REGN?
Veritas In Silico's EBIT of 円-437.89 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Biotechnology company?
A good EBIT depends on the Biotechnology industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Veritas In Silico. Veritas In Silico's current EBIT is 円-437.89 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Veritas In Silico stock overvalued right now?
Based on GuruFocus' analysis, Veritas In Silico (TSE:130A) is currently considered Significantly Overvalued. The stock's GF Value™ is 円266.78, compared to a current price of 円433.00 — trading 62.3% above its estimated fair value. The current EBIT is 円-437.89 Mil. Veritas In Silico's overall GF Score™ is 28/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Veritas In Silico (TSE:130A), the current EBIT is 円-437.89 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Veritas In Silico (TSE:130A) Overvalued in 2026?

Based on GuruFocus' analysis, Veritas In Silico stock appears to be overvalued. The current stock price of 円433.00 is trading 62.3% above its estimated GF Value™ of 円266.78. GuruFocus considers Veritas In Silico to be Significantly Overvalued.

Key valuation signals for TSE:130A:

  • EBIT: 円-437.89 Mil
  • GF Value™: 円266.78 vs. price of 円433.00 (62.3% above fair value)
  • GF Score™: 28/100 with 4 warning signs

No single metric tells the full story. See the TSE:130A stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Veritas In Silico Business Description

Address 1-11-1, Nishigotanda, Shinagawa-ku, Tokyo, JPN, 141-0031
Veritas In Silico Inc is engaged in discovery of mRNA-targeted small molecule and antisense oligonucleotide drugs. It has ibVIS platform that combines informatics (i) and experimental biology at Veritas In Silico (VIS) that will bring to fruition mRNA-targeted drugs.
28GF Score

Get the complete analysis for TSE:130A

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円433.00
Price
円266.78
GF Value